ClinicalTrials.gg
Enrolling by invitationNCT07324928CTUpdated Mar 9, 2026

Effect of Ferric Sulphate and Putty MTA as Pulpotomy Agent in Vital Primary Teeth

An interventional study of Ferric sulphate and Putty MTA in Pulptomy, Dental Caries and Pulp Therapy, sponsored by University of Jazan. Enrolling by invitation at 1 site in Saudi Arabia. Open to participants aged 6 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by University of Jazan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Dental Caries with a site in Saudi Arabia — 3 open to participants now, 5 under way, none of them phase 3. Dental Caries · Saudi Arabia.

Planned enrollment
10th of 22
60 · median 60
Started
2026
with 1 other
No phase
13 of 23
1 open now
Registered
17th of 23
by date
Lead sponsor
3 of 23
University of Jazan

Among the 23 studies in Dental Caries with a site in Saudi Arabia, this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 17th registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

3 of the 23 studies in Dental Caries with a site in Saudi Arabia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Saudi Arabia have not opened yet or have stopped. Only those recruiting at a site in Saudi Arabia →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dental Caries with a site in Saudi Arabia, or all of them as a file.
02

Study summary

The pulp in primary teeth has a high potential for repair because of high degree of cellularity and vascularity. The rationale for the pulpotomy procedure is that the radicular pulp tissue is healthy and capable of healing after surgical amputation of the affected or the infected coronal pulp. There is ample information about pulpotomy in deciduous molars using formocresol, glutaraldehyde, electrosurgery, ferric sulphate, calcium hydroxide, MTA etc. The vital pulpotomy process using formocresol has been widely accepted in primary tooth pulp therapy because of its simplicity and good prognosis. However, much concern as arisen over the mutagenic and carcinogenic potential of formaldehyde containing products, the cytotoxic effects of formocresol and the possible diffusion into the surrounding and systemic tissues. In order to avoid the possible harmful effects of formocresol; other pulpotomy agents for vital pulpotomy procedure is being sought such as ferric sulphate and MTA with promising results due to their advantages such as devitalization and regenerative agents respectively.

Ferric sulphate [Fe2(SO4)3] as a 15.5% solution is a coagulative and local hemostatic agent.

Ferric sulphate is a material with minimal devitalization and non-induction of pulp tissue. It is used as a coagulative and hemostatic retraction agent. Ferric sulfate is proposed as a pulpotomy agent on the theory that its mechanism of controlling hemorrhage might minimize the chances for inflammation. Ranly proposes the possibility that the metal-protein clot at the surface of the pulp stumps may act as a barrier to the irritative components of the sub-base which helps in minimizing the complications from the material. The hemostatic properties of ferric sulfate and the favorable pulpal response make it a promising medicament for pulpotomy. Erdem AP et al in their study observed no significant differences among 3 experimental materials MTA, Formocresol and Ferric sulphate. Fei AL et al observed clinical ad radiographic success than the Formocresol group at the end of one year.

Mineral trioxide aggregate (MTA) is one such regenerative material recognized as the reference material for conservative pulp vitality treatments in primary teeth, with high pulpotomy success rates (90%-100%) in clinical, radiographic, and histopathologic studies. However, MTA has difficult handling characteristics, contains heavy metals such as alumina and bismuth oxide, and is expensive. Technological improvements in the medical meteorology led to development and innovations in bioceramic nanotechnology (Bioceramics) which exhibit excellent biocompatibility with properties in unison with hydroxyapatite. Recently, bioceramic putty, a calcium silicate based nanoparticulate material, was introduced into dentistry as a root repairing material. It is an insoluble, radiopaque, aluminum free, and zirconium oxide incorporated material developed for potential dental surgery applications. Moreover, it stimulates the deposition of hydroxyapatite on its surface when exposed to tissue fluids, forms well organized dentin, and has low cytotoxicity. Despite its ease of handling, high viscosity, shorter setting time, better physical properties over MTA and the biomimetic property of bioceramics, its clinical application in the field of vital pulp therapy in primary teeth has not been explored so far. Kumar KR et al in their study showed clinical success rate of 95 % and radiographic success rate of around 90% with MTA.

Some studies have reported internal resorption seen with ferric sulphate pulpotomy, sensitivity, premature tooth loss , furcation radiolucency, gingival swelling but not attributed the exact reason for the same. They attributed to tooth selection for the procedure. Hence proper tooth selection is a criteria for the success of pulpotomy.

Read the detailed description

Pilot study will not be conducted as we are not testing the feasibility of the methodology.

This study will be performed on 60 patients aged 6 to 10 years attending the clinics of department of paediatric dentistry, college of dentistry, Jazan university will be considered for the study.

Before starting; the procedure will be explained; verbal and written consent will be obtained by the parent or guardian. After obtaining consent a total of 60 molars will be randomly divided into two groups, Group A with ferric sulphate and Group B with Putty MTA using a lottery randomization technique.

Pulpotomy will be done in both the groups followed by GIC restoration. Immediate post operative radiograph will be taken for all the patients. The patients will be recalled at 1month and 3 month and 6-month interval for clinical and radiographic evaluation.

In recall visits all the teeth will be evaluated to grade them as either success or failure based on the clinical and radiographic criteria. This will be evaluated by investigators unaware of the group assignment.

Criteria for evaluating the success:

Teeth which presented with no symptoms of pain. Tenderness to percussion, swelling, fistulation, or pathologic mobility clinically as well as no evidence of radicular radiolucency, internal or external root resorption or periodontal ligament space widening radiographically will be considered successful. Any tooth which showed signs of symptoms of failure will be treated with pulpectomy

03

Conditions studied

  • Pulptomy
  • Dental Caries
  • Pulp Therapy

Browse trials for

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy children with no systemic illness, allergies
  2. Co-operative child
  3. Patient requiring pulpotomy on deciduous molars with carious /mechanical pulp exposure
  4. children with proper parental consent
  5. No clinical or radiographical signs of pulp pathoses
  6. Possibility of proper restoration of tooth after the procedure
  7. Haemostasis should be easily achievable after pulp amputation

Exclusion criteria

Exclusion criteria

  1. Children with systemic illness and allergy
  2. Un co-operative child
  3. clinical or radiographical signs of pulp pathoses
  4. unrestorable tooth
  5. Haemostasis not achieved after pulp amputation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A (Ferric Sulphate)

    already described

    Procedure: Ferric sulphate

  • Experimental
    Group B ( Putty MTA)

    already described

    Procedure: Putty MTA

Interventions

  • ProcedureFerric sulphate

    already described

  • ProcedurePutty MTA

    already described

06

What researchers measure

Primary outcomes

  1. Clinical criteria

    Clinical Teeth which presented with * no symptoms of pain. * Tenderness to percussion, * swelling, * fistulation, or * pathologic mobility

    Time frame: 1 month, 3 month , 6 month

  2. Radiographic criteria

    * Evidence of radicular radiolucency, * Internal or external root resorption * Periodontal ligament space widening

    Time frame: 1 month, 3 month, 6 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2026, 2 months after the start.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 8, 2026
StartActual
Mar 7, 2026
Primary completionEst.
May 28, 2026
CompletionEst.
May 28, 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07324928
Lead sponsor
University of Jazan
Responsible party
satish vishwanathaiah (Associate professor, University of Jazan) — Principal investigator
First posted
Jan 8, 2026
Start date
Mar 7, 2026
Primary completion
May 28, 2026 (estimated)
Completion
May 28, 2026 (estimated)
Last update
Mar 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion